SF developers blueprint $1B biotech campus

South San Francisco may be suffering from high commercial vacancy rates, but Shorenstein Properties and SKS Investments have reached a deal with the city to begin building a billion dollars worth of new biotech lab and office space. The developers are blueprinting 2.3 million square feet of new R&D space on the waterfront at Oyster Point.

"It's a $1 billion project," Marty Van Duyn, the city's director of economic development, tells the San Francisco Business Times. "It's a lot of good R&D and office, and they are helping us out quite a bit in realizing our long-term goals for the harbor in terms of recreation and retail and open space. It presents a unique opportunity to marry some of the city's goals with a major development. This area has languished for a long period of time. It has not been as popular as it should be."

When it's done, the new biotech campus is expected to become a new workplace for 8,000 people. And the developers plan to begin construction at a time that the office vacancy rate is close to 20 percent, with about 800,000 square feet available.

- read the story from the San Francisco Business Times

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.